Medicare Should Cover Weight Loss Drugs as Long as the Prices are Affordable.
Catherine S HwangAaron S KesselheimBenjamin N RomePublished in: The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics (2024)
Glucagon-like peptide-1 receptor agonists are effective for treating obesity, but the high cost of these medications endangers the financial viability of our health care system. To ensure that these drugs are available to Medicare beneficiaries, pharmaceutical manufacturers must lower their prices.